Yahoo Finance

Scribe Therapeutics Awarded More Than $25 Million From CIRM to Accelerate Additional CRISPR-Based Gene Editing Therapies for Cardiometabolic Disease Into Clinical Trials

ALAMEDA, Calif., June 18, 2026--(BUSINESS WIRE)--Scribe Therapeutics, Inc. (Scribe), a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR technologies designed to extend ...
GEN

Scribe Pursues CRISPR Therapies with Expanded Biogen Collaboration

Scribe Therapeutics Co-Founder, President and CEO Benjamin L. Oakes, PhD A year and a half into a collaboration with Biogen to develop CRISPR-based therapies, Scribe Therapeutics says the companies ...
Business Wire

Scribe Therapeutics to Present on Advances in CRISPR Genome and Epigenome Editing at the 2024 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

Company will highlight developments enabled by its CRISPR by Design™ approach to engineer novel in vivo genetic medicines, including for ophthalmic diseases ALAMEDA, Calif.--(BUSINESS WIRE)--Scribe ...
Business Wire

Scribe Therapeutics Presents Data on its X-Editing Technologies at 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

Data demonstrate proprietary X-Editors engineered using Scribe’s CRISPR by Design™ approach are a promising gene editing platform for developing genetic medicines with high activity, specificity and ...
Morningstar

Scribe Therapeutics Reports Preclinical Data at ASGCT 2026 Demonstrating Enhanced Potency and Specificity of Engineered CRISPR Technologies for Epigenetic Silencing and Gene ...

Oral presentation on novel allosteric ELXR epigenetic silencer showcases Scribe’s development in achieving highly precise, potent, and durable target repression XE gene editor oral presentation ...
GEN

Lilly Subsidiary, Scribe Ink Up-to-$1.5B CRISPR-Based Neuro Collaboration

Benjamin L. Oakes, PhD, Scribe Therapeutics co-founder, president, and CEO Scribe Therapeutics will partner with Prevail Therapeutics, a wholly owned subsidiary of Eli Lilly, to develop in vivo CRISPR ...
Morningstar

Scribe Therapeutics Awarded More Than $25 Million From CIRM to Accelerate Additional CRISPR-Based Gene Editing Therapies for Cardiometabolic Disease Into Clinical Trials

Scribe received multi-year grant awards from the California Institute for Regenerative Medicine (CIRM) to advance two therapeutic programs from Scribe’s comprehensive, wholly-owned cardiometabolic ...